Webbläsaren som du använder stöds inte av denna webbplats. Alla versioner av Internet Explorer stöds inte längre, av oss eller Microsoft (läs mer här: * https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Var god och använd en modern webbläsare för att ta del av denna webbplats, som t.ex. nyaste versioner av Edge, Chrome, Firefox eller Safari osv.

Clinical Protein Science and Targeted Mass Spectrometric Assays - New Frontiers in Disease Link and Biobanking

Författare

Redaktör

  • Joshua LaBaer
  • Manuel Fuentes

Summary, in English

Today’s societies have to reach out for improved healthcare solutions due to the increased number of patients and changed disease profiles represented by the dominance of cardiovascular and neurodegenerative diseases as well as various forms of cancer that require customized therapies. There is an extensive need for diagnostic and therapeutic biomarkers that may also become targets for drug developments in the future. Modern analytical platforms headed by mass spectrometry offer enhanced sensitivity as well as novel methodologies with extreme specificity to identify and quantify these potential protein markers in clinical studies, which is in the focus of international research organized by the Human Proteome Organization. However, the complexity of clinical samples and the wide concentration range of proteins represent analytical tasks yet need to be accomplished. In this chapter we present the challenges the healthcare systems face nowadays and outline possible solutions using biobanking standardization, personalized medicine and mass spectrometric technologies with relevant examples.

Publiceringsår

2014

Språk

Engelska

Sidor

157-173

Publikation/Tidskrift/Serie

Proteomics: Targeted Technology, Innovations and Applications

Dokumenttyp

Del av eller Kapitel i bok

Förlag

Horizon Scientific Press

Ämne

  • Medical Engineering

Status

Published

ISBN/ISSN/Övrigt

  • ISBN: 978-1-908230-46-1